Clinicopathological and Prognostic Significance of CXCR4 Expression in Osteosarcoma: A Meta-Analysis

Kusuma, I Gusti Ngurah Ananda Wira; Yapson, Grace Yulia Alphani; Nolan, John; Wiratnaya, I Gede Eka; Supadmanaba, I Gede Putu

doi:10.37796/2211-8039.1360

Cited by 1 publication

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natalizumab, a monoclonal antibody specific to alpha-4 integrin, is being tested in a phase I/II clinical trial in patients between the ages of 5 to 30 with recurrent refractory pulmonary metastatic OS (NCT03811886). A meta-analysis confirmed another molecule associated with metastasis in OS: CXCR4 [81]. Our laboratory has previously shown in a rhabdomyosarcoma animal model that targeting CXCR4 with a monoclonal antibody in combination with activated and expanded NK-cell therapy prevented lung metastasis and tumor implantation [82].…”

Section: Low Number Of Tumor-associated Antigensmentioning

confidence: 73%

Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas

Bareke,

Ibáñez-Navarro,

Guerra-García

et al. 2023

IJMS

View full text Add to dashboard Cite

Malignant bone tumors are aggressive tumors, with a high tendency to metastasize, that are observed most frequently in adolescents during rapid growth spurts. Pediatric patients with malignant bone sarcomas, Ewing sarcoma and osteosarcoma, who present with progressive disease have dire survival rates despite aggressive therapy. These therapies can have long-term effects on bone growth, such as decreased bone mineral density and reduced longitudinal growth. New therapeutic approaches are therefore urgently needed for targeting pediatric malignant bone tumors. Harnessing the power of the immune system against cancer has improved the survival rates dramatically in certain cancer types. Natural killer (NK) cells are a heterogeneous group of innate effector cells that possess numerous antitumor effects, such as cytolysis and cytokine production. Pediatric sarcoma cells have been shown to be especially susceptible to NK-cell-mediated killing. NK-cell adoptive therapy confers numerous advantages over T-cell adoptive therapy, including a good safety profile and a lack of major histocompatibility complex restriction. NK-cell immunotherapy has the potential to be a new therapy for pediatric malignant bone tumors. In this manuscript, we review the general characteristics of osteosarcoma and Ewing sarcoma, discuss the long-term effects of sarcoma treatment on bones, and the barriers to effective immunotherapy in bone sarcomas. We then present the laboratory and clinical studies on NK-cell immunotherapy for pediatric malignant bone tumors. We discuss the various donor sources and NK-cell types, the engineering of NK cells and combinatorial treatment approaches that are being studied to overcome the current challenges in adoptive NK-cell therapy, while suggesting approaches for future studies on NK-cell immunotherapy in pediatric bone tumors.

show abstract

Section: Low Number Of Tumor-associated Antigensmentioning

confidence: 73%